OtherClinical Investigations (Human)
Open Access

Evaluation of safety and dosimetry of 177Lu DOTA-ZOL for therapy of bone metastases

Rene Fernandez, Elisabeth Eppard, Wencke Lehnert, Luis David Jimenez-Franco, Cristian Soza-Ried, Matias Ceballos, Jessica Ribbeck, Andreas Kluge, Frank Roesch, Marian Meckel, Konstantin Zhernosekov, Vasko Kramer and Horacio Amaral
Journal of Nuclear Medicine January 2021, jnumed.120.255851; DOI: https://doi.org/10.2967/jnumed.120.255851

Article Information

jnumed.120.255851
DOI 
https://doi.org/10.2967/jnumed.120.255851
PubMed 
33419945
Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 8, 2021.
Copyright & Usage 
Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Rene Fernandez1,
  2. Elisabeth Eppard2,
  3. Wencke Lehnert3,
  4. Luis David Jimenez-Franco3,
  5. Cristian Soza-Ried1,
  6. Matias Ceballos1,
  7. Jessica Ribbeck2,
  8. Andreas Kluge3,
  9. Frank Roesch4,
  10. Marian Meckel5,
  11. Konstantin Zhernosekov5,
  12. Vasko Kramer2 and
  13. Horacio Amaral2
  1. 1 Center for Nuclear Medicine & PET/CT Positronmed;
  2. 2 Positronpharma SA, Chile;
  3. 3 ABX-CRO, Germany;
  4. 4 Institute of Nuclear Chemistry, Johannes Gutenberg-University, Germany;
  5. 5 Isotope Technologies Garching GmbH, Germany
  1. For correspondence or reprints contact: Elisabeth Eppard, Positronpharma SA, Rancagua 878, Providencia, Santiago 7500921, Chile. E-mail: eeppard@positronpharma.cl

Article usage

Article usage: to

AbstractFullPdf
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords